home / stock / rgls / rgls quote
Last: | $2 |
---|---|
Change Percent: | 0.5% |
Open: | $2.01 |
Close: | $2 |
High: | $2.11 |
Low: | $1.95 |
Volume: | 240,786 |
Last Trade Date Time: | 05/16/2024 03:00:00 am |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$2 | $2.01 | $2 | $2.11 | $1.95 | 240,786 | 05-16-2024 |
$2.02 | $2.09 | $2.02 | $2.13 | $1.94 | 605,591 | 05-15-2024 |
$2.08 | $2.1 | $2.08 | $2.17 | $2.01 | 568,184 | 05-14-2024 |
$2.09 | $2.21 | $2.09 | $2.28 | $2.03 | 543,864 | 05-13-2024 |
$2.21 | $2.13 | $2.21 | $2.34 | $2.13 | 659,058 | 05-10-2024 |
$2.25 | $2.26 | $2.25 | $2.355 | $2.2 | 613,612 | 05-09-2024 |
$2.27 | $2.2 | $2.27 | $2.32 | $2.16 | 446,129 | 05-08-2024 |
$2.23 | $2.43 | $2.23 | $2.49 | $2.18 | 704,792 | 05-07-2024 |
$2.43 | $2.71 | $2.43 | $2.789 | $2.4 | 891,068 | 05-06-2024 |
$2.65 | $2.83 | $2.65 | $2.83 | $2.64 | 406,153 | 05-03-2024 |
$2.69 | $2.53 | $2.69 | $2.9 | $2.49 | 709,956 | 05-02-2024 |
$2.51 | $2.3 | $2.51 | $2.67 | $2.21 | 562,861 | 05-01-2024 |
$2.3 | $2.51 | $2.3 | $2.5893 | $2.3 | 234,803 | 04-30-2024 |
$2.52 | $2.44 | $2.52 | $2.6 | $2.41 | 214,214 | 04-29-2024 |
$2.42 | $2.3 | $2.42 | $2.485 | $2.27 | 204,765 | 04-26-2024 |
$2.27 | $2.27 | $2.27 | $2.29 | $2.17 | 97,798 | 04-25-2024 |
$2.22 | $2.29 | $2.22 | $2.29 | $2.22 | 91,807 | 04-24-2024 |
$2.26 | $2.17 | $2.26 | $2.34 | $2.13 | 101,492 | 04-23-2024 |
$2.2 | $2.09 | $2.2 | $2.26 | $2.09 | 127,753 | 04-22-2024 |
$2.13 | $2.23 | $2.13 | $2.31 | $2.09 | 222,754 | 04-19-2024 |
News, Short Squeeze, Breakout and More Instantly...
Regulus Therapeutics Inc. Company Name:
RGLS Stock Symbol:
NASDAQ Market:
Regulus Therapeutics Inc. Website:
Regulus Therapeutics Announces Promotion of Rekha Garg, M.D., M.S., to Chief Medical Officer PR Newswire SAN DIEGO , May 16, 2024 /PRNewswire/ -- Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of inn...
Regulus Therapeutics Reports First Quarter 2024 Financial Results and Recent Updates PR Newswire Initiated the fourth cohort of patients in the Phase 1b multiple-ascending dose (MAD) clinical trial of RGLS8429 for the treatment of autosomal dominant polycystic kidney disea...